Introduction
============

The toxicity of 4-methylimidazole (4MeI) is a matter of concern both in human and veterinary toxicology ([@b14]; [@b2]). The substance was first identified as a tremorogenic and convulsive agent by [@b17], after the observation of violent signs of CNS toxicity in cattle fed ammoniated molasses ([@b24]). 4MeI induces the same signs of toxicity whether it is given orally or parenterally. [@b17] determined the po LD~50~ to 370 mg/kg, and the ip LD~50~ to 165 mg/kg.

The mechanism behind the excitatory and convulsive effects of 4MeI is not known. The effects can be counteracted by chlordiazepoxide and by sodium phenobarbital ([@b17]). Both these drugs are considered to exert their main effect via GABA~A~ receptors in the brain ([@b3]). Similarity of the clinical signs induced by 4MeI and by known inhibitors of GABA synthesis such as mercaptopropionic acid and mercaptobutyric acid ([@b10]; [@b8]) does also hint at the GABA system as a possible target for 4MeI toxicity. In experimental 4MeI poisoning, sudden appearance of dramatic convulsions after a dose-dependent latent period is characteristic ([@b22]). This picture could be consistent with a build-up or depletion mechanism in the mouse brain, such as the depletion of cerebral GABA levels induced by inhibitors of cerebral GAD activity ([@b8]).

On this background, the present study was designed to clarify if 4MeI has sufficient effect on cerebral GABA synthesis or on specific GABA receptor binding to explain the excitatory and convulsive effects of the substance. The study was divided into three parts: an investigation of the effects of 4MeI on mouse brain glutamate decarboxylase (GAD) activity in vitro, an investigation of the effects of acute 4MeI poisoning on the immediate post-mortem GABA and glutamate concentrations in the mouse brain, and an investigation of the effects of 4MeI on specific \[^3^H\]GABA receptor binding in mouse brain synaptosomal membranes in vitro.

Materials and methods
=====================

Animals
-------

All animals were B6D2 mice (Norwegian Institute of Public Health, Oslo). They were caged in groups of 10 with free access to food and tap water, with a 12-hour light/day cycle, a relative humidity of 50%, and a room temperature of 25°C. Ca 60 animals were used altogether. The experimental work was conducted at and approved by the Norwegian Defence Research Establishment at Kjeller, Norway. The experimental animals were handled in accordance with institutional and national guidelines for animal research.

Effect of 4MeI on GAD activity
------------------------------

GAD can be obtained in a soluble form after hypotonic shock of nerve terminals ([@b4]). B6D2 mice were euthanized by cervical dislocation. The brain was taken out and homogenized in 20 volumes of 0.32 M sucrose. The homogenate was centrifuged at 700 ×g for 10 minutes. The pellet was discarded and the supernatant centrifuged at 13 000 ×g for 30 minutes. The pellet from this centrifugation was shocked with cold, distilled water, re-homogenized and centrifuged at 20 000 ×g for 30 minutes. The supernatant, hereafter referred to as brain enzyme extract, was used for the GAD assays.

GAD activity was assayed by a modified version of the radiochemical method described by [@b1] and [@b5]. The brain enzyme extract (2 μl) was mixed with varying concentrations of 4MeI and with a prepared incubation solution, to a total volume of 4 μl in each test tube. The final mixture contained 11 μCi/ml Na L-\[1-^14^C\]-glutamate, 9.2 mM Na L-glutamate, 9.3 μM pyridoxal phosphate, 0.84 mM dithiotreitol, 18.9 mM NaH~2~PO~4~ buffer, and 0.24% Triton X-100. The final pH was 6.5. The final 4MeI concentrations used were 5 μM, 50 μM, 100 μM, 500 μM, 1 mM, 2 mM, 5 mM, and 10 mM.

The assay was run four times with each 4MeI concentration, with controls (without 4MeI) and with blanks (without brain enzyme extract). Through previous experiments it was confirmed that the activity recorded was linear with the amount of GAD enzyme ([@b5]). The whole experiment was repeated three times, and the results calculated as activity in percent of controls. Thereafter, GAD activity assays were repeated with the following variations in experimental conditions: with 4MeI concentration fixed at 5mM, the assays were run with Na L-glutamate concentrations of 9.2 mM, 2.3 mM, and 575 μM. With 4MeI concentration at 5 mM and Na L-glutamate at 2.3 mM, the assays were also run with pyridoxal phosphate concentrations of 9.3 μM, 4.7 μM, 2.3 μM, 0.9 μM, and 0 μM. The assay was run at least six times for each set of concentrations.

With Na-L glutamate concentration at 2.3 mM and pyridoxal phosphate at 9.3 μM, a comparative study of the effects of the following substituted imidazoles were carried out, in concentrations from 5--20 mM (minimum of six repeats per substance and concentration): 4MeI, 1-methyl imidazole (1MeI), 2-methyl imidazole (2MeI), 4-hydroxymethyl imidazole (4MeOHI), and imidazole-4-acetic acid (4AcI). In addition, the effect of 20 mM unsubstituted imidazole was tested.

Concentrations of GABA and glutamate in mouse brain after lethal poisoning with 4MeI
------------------------------------------------------------------------------------

Ten B6D2 mice, weighing 31--39 g, were used. Mouse no. 1 was given 250 mg 4MeI/kg body weight ip, and mouse no. 2 was given an equal volume of 0.9% NaCl solution ip immediately afterwards, to serve as control. When mouse no. 1 developed violent convulsions and died ([@b22]), mouse no. 2 was immediately euthanized by cervical dislocation. The same procedure was repeated with mice no. 3 and 4, no. 5 and 6, etc.

The heads of the dead and euthanized mice were immediately cooled in liquid N~2~, and the brains were dissected out on ice. Each brain was homogenized in 6 ml 2.5% trichloroacetic acid, with 0.5 mM α-aminoadipic acid added as internal standard. The homogenate was centrifuged for 10 minutes at 15,000 rpm. The supernatant was extracted three times with ethyl ether to remove non-polar substances. Concentrations of glutamate and GABA in the supernatant were measured by the method of [@b11], as modified by [@b21], applying precolumn o-phtaldialdehyde derivatization. The samples were injected on a Varian 500LC apparatus with a reversed-phase Supelcosil LC-18-DB column, a mixture of 50 mM NaH~2~PO~4~ buffer (pH 5.25) and methanol as mobile phase, and a CMA/280 fluorescence detector. Gradient eluation was used, with the amount of NaH~2~PO~4~ buffer changing from 75% to 25% over 20 minutes ([@b20]). The protein concentration in the pellet was measured by reaction with Folin-Ciocalteu reagent and analysis with a spectrophotometer at 750 nm, according to [@b12]. GABA and glutamate concentrations in the mouse brains were calculated as μMol/mg protein.

Effect of 4MeI on \[^3^H\]GABA binding to cerebral GABA receptors
-----------------------------------------------------------------

The effect of 4MeI on sodium independent binding of \[^3^H\] GABA to synaptosomal membranes from mouse brain was investigated with a modified version of the method described by [@b7] and [@b16]. Brains from B6D2 mice were homogenized in 20 volumes of 0.32 M sucrose and centrifuged at 1000×g for 10 minutes, and the pellet was washed once. The combined supernatants were then centrifuged at 20 000 ×g for 20 minutes. The pellet from this centrifugation was resuspended to the same volume with cold, distilled water to rupture membrane vesicles, and kept on ice for 1 hour. After centrifugation at 8000 ×g for 20 minutes the supernatant was gently decanted, and the upper layer of the pellet was rinsed off and added to the supernatant. These combined supernatants were recentrifuged at 48 000 ×g for 20 minutes, and the pellet stored frozen at −20°C prior to use. For the receptor binding assay, the membranes were thawed, resuspended in TrisHCl buffer (50 mM, pH 7.4), and incubated for 45 minutes at room temperature before centrifugation (8500 ×g for 10 minutes). The membrane suspension was further washed three times and incubated with the Tris-buffer for 15 minutes at room temperature between each centrifugation, to remove all endogenous ligand. The final pellet was resuspended to give a protein concentration of ca. 100 μg per assay.

Binding of \[^3^H\]GABA (final concentration 25 nM with a specific activity of 40 Ci/mmol) was assayed in the absence or presence of 1 mM unlabeled GABA, to determine the specific transmitter binding. Varying amounts of 4MeI (0, 5 μM, 50 μM, 100 μM, 500 μM, 1 mM, 2 mM, 5 mM, and 50 mM final concentration) were added. All assay mixtures were diluted to a final volume of 500 μl with TrisHCl, before incubation for 60 minutes at 0°C. The membranes were collected on filters with a Skatron cell harvester, the filters were transferred to scintillation cups, dissolved in 10 ml Filter Count counting liquid and counted in a Packard 2200CA liquid scintillation analyzer. Three parallel assays without and two with unlabeled GABA were run for each 4MeI concentration. The complete series of assays was repeated four times, and the results calculated as GABA receptor binding in per cent of the mean binding without 4MeI.

Statistical analysis
--------------------

In all comparisons, student\'s *t*-test was used for statistical evaluation. Unless stated otherwise, the limit of statistical significance was set at *p* \< 0.05.

Results
=======

In the first set of experiments on cerebral GAD activity, 4MeI concentrations from 5 μM to 1 mM did not reduce GAD activity significantly, compared to control values. With 2 mM 4MeI the GAD activity was reduced to 85.4% of controls (SD 4.9%), with 5 mM to 77.9% (SD 7.1%), and with 10 mM 4MeI to 61.7% of controls (SD 10.4%). All these reductions were statistically significant (*p* \< 0.05).

With the 4MeI concentration set at 5 mM, neither variation of pyridoxal phosphate concentrations in the assay mixture from 0.9--9.3 μM nor variation of glutamate concentrations from 575 μM to 9.2 mM did affect the influence of 4MeI on GAD activity significantly.

In the comparative experiment, all the substituted imidazoles tested reduced the GAD activity significantly (*p* \< 0.01) in concentrations from 5--20 mM. In equal concentrations, 2MeI had stronger effect on GAD activity than 4MeI ([Figure 1](#fig1){ref-type="fig"}). Twenty mM imidazole also reduced the GAD activity (*p* \< 0.01), but with somewhat less effect (83.1% of control) than the substituted imidazoles.
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After ip injection of 250 mg 4MeI/kg, all the mice tested developed sudden convulsive seizures, after a lag period varying from 3 minutes 50 seconds to 6 minutes 50 seconds. They died in a few seconds after the onset of seizures. Average postmortem cerebral GABA concentrations in the poisoned mice were 22.1 μMol (SD 1.8 μMol) per mg protein, compared to 20.3 μMol (SD l.0 μMol) per mg protein in the control mice. The average cerebral glutamate concentrations were 119.7 μMol (SD 9.8 μMol) per mg protein in the poisoned mice, and 114.6 μMol (SD 8.2 μMol) per mg protein in the controls. None of the differences between poisoned and control mice were statistically significant.

4MeI concentrations from 5 μM to 2mM did not have a significant effect on sodium independent binding of \[^3^H\]GABA to synaptosomal membranes from mouse brain. With 5 mM 4MeI present the \[^3^H\]GABA binding was significantly (*p* \< 0.01) reduced; to 63.4% (SD 7.2%) of control values. With 50 mM 4MeI the binding was reduced to 23.9% (SD 3.7%) of controls (*p* \< 0.01).

Discussion
==========

Since the original report of [@b24], poisoning of ruminants by ammoniated forage has been observed worldwide. The poisoning is characterized by sudden episodes of agitated confusion, hyperexcitability, tremors, and convulsions ([@b14]). 4MeI was for many years generally accepted as the main etiologic agent in this poisoning syndrome ([@b19]). Findings of very low concentrations of 4MeI in the feed and plasma of experimentally poisoned animals have complicated the picture ([@b23]; [@b14]). Still, 4MeI is up to now the strongest and most abundant convulsive agent identified in poisonous ammoniated forage ([@b15]), and the clinical signs of experimental 4MeI poisoning are indistinguishable from those of poisoning with ammoniated feed ([@b9]). Clonic seizures and hyperactivity have also been observed after oral exposure to 4MeI in long-term feeding studies in rats ([@b2]).

In lethal doses, the effect of 4MeI in mice is characteristic and dramatic. Shortly after parenteral administration of 250 mg/kg 4MeI the treated mouse may show moderate signs of CNS excitation: Raised tail, slight tremors, small squeaks and jumps, and repeated grooming of the muzzle with its fore paws. After a period of 3--7 minutes, the mouse goes suddenly into violent convulsions, similar to those described by [@b6] as running-bouncing clonic seizures. Within a short time, usually a few seconds, the seizures end in a typical tonic extensor convulsive spasm ([@b6]) and death ([@b22]). This toxicological picture requires that the number of animals used in in vivo studies should be kept as low as possible ([@b22]). Accordingly, the number of mice given toxic 4 MeI doses in the present study was restricted to five. From a mechanistic point of view, the clinical picture of acute 4MeI poisoning does in our opinion indicate that 4MeI interferes with one or more of the major transmitter systems in the brain ([@b6]; [@b13]).

In the present study, 4MeI was found to have a dose-dependant inhibitory effect on GAD activity in vitro, statistically significant at concentrations of 2 mM or above. An average whole brain 4MeI concentration of 2.2 mMol/kg has been found in mice after lethal poisoning with 250 mg/kg (Sivertsen, Hassel, and Uhlig, unpublished), so the inhibitory concentrations in vitro are just within the range of relevant in vivo concentrations. In contrast, both mercaptopropionoic acid and mercaptobutyric acid show significant inhibition of GAD in vitro already at concentrations of 0.1--0.5 mM ([@b10]). Neither variation in glutamate concentrations nor of pyridoxal phosphate concentrations in the assay changed the strength of the inhibitory effect. This indicates that the inhibition of GAD was not competitive with regard to substrate or coenzyme in the enzymatic process. This is in contrast to the effect of mercaptopropionic acid, which is clearly competitive with respect to glutamate ([@b10]). Our testing of other substituted imidazoles showed that they all had an inhibitory effect on GAD activity in the same range, with 2MeI giving the strongest inhibition of GAD. This is in contrast to experiments in vivo, where 1MeI and 2MeI show much weaker tremorogenic and convulsive activity than 4MeI ([@b17]). Finally, lethal poisoning of mice with 4MeI did not change the cerebral levels of GABA, in strong contrast to the effect seen with mercaptopropionic acid ([@b8]). Taken together, these results do not confirm inhibition of cerebral GABA synthesis as a decisive mechanism in 4MeI toxicity.

In the GABA receptor binding experiments, 4MeI was found to inhibit specific binding of \[^3^H\]GABA to cerebral GABA receptors, but the inhibition was statistically significant only in concentrations at 5 mM or above, and 50 mM was needed to inhibit the GABA receptor binding with 76%. As mentioned, these concentrations are higher than the whole brain concentrations of 4MeI after lethal poisoning. Therefore, also the inhibition of GABA receptor binding seems too weak to be a main mechanism in 4MeI CNS toxicity.

In conclusion, the results of this study do in our opinion indicate that neither 4MeI inhibition of GABA synthesis nor interference with specific GABA receptor binding in mouse brain provide a satisfactory explanation of the convulsive effect of 4MeI in mice.

As mentioned in the introduction, [@b17] found that the convulsive effect of 4MeI could be counteracted by chlordiazepoxide and by sodium phenobarbital. Although benzodiazepines and barbiturates are known to act via the GABA~A~ receptor, both groups have a clinically broad anticonvulsive effect, counteracting seizures induced by different agents and pathological mechanisms ([@b13]). The possibility that the convulsive effect of 4MeI is related to interference with cerebral GABA activity cannot yet be finally excluded, as some GABA receptor inhibitors like picrotoxin bind to other receptor sites than GABA itself ([@b18]). Still, our results do indicate that the effect of 4MeI on other receptor systems in the mammalian brain should be investigated.
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